
Anne McDonald Pritchett, PhD Anne McDonald Pritchett, Ph.D., is Senior Vice President, Policy and Research, at the Pharmaceutical Research and Manufacturers of America (PhRMA). Her primary focus is overseeing the development of legislative and policy analysis and research studies on a range of issues impacting innovative biopharmaceutical companies including intellectual property issues, FDA policy issues, and other issue areas impacting the environment for innovation. In addition to her public policy work, she and her team lead the development of a range of educational and other materials focused on explaining the R&D process, the value of innovation, and the role and contributions of the innovative biopharmaceutical industry.
Recent Posts
Seizing the opportunity to rebuild U.S. leadership in STEM

The United States is not only falling behind other countries on many key science, technology, engineering and mathematics (STEM) indicators, but our public investment in STEM education has steadily...
Read More
Stopping opioid abuse

According to the U.S. Centers for Disease Control and Prevention (CDC), more than 14,000 people died from overdoses involving opioids in 2014—a four-fold increase since 2009. The agency has declared...
Read More
New Report: Innovation in the Biopharmaceutical R&D Process – Adapting to a Changing Environment

With the average cost of developing, testing and receiving approval for a new medicine at $2.6 billion and rising, biopharmaceutical companies are continuously looking at new ways to increase...
Read More
Upcoming Forum on Improving Critical Tools for Preventing Prescription Drug Abuse

On June 2, the Network for Excellence in Health Innovation (NEHI) will bring experts from across the country to Boston to discuss a critical public health challenge—the abuse of prescription...
Read More
Earth Day 2015: Green Initiatives are Good for Business and the Environment

Earth Day provides us all with an opportunity to consider the role each of us can play in protecting the Earth’s natural resources. The nation’s innovative biopharmaceutical companies spend...
Read More
Maintaining Appropriate Incentives for Biopharmaceutical Innovation

As we enter the second half of the decade, the biopharmaceutical industry’s approach to research and development (R&D) continues to evolve to meet the growing demand for new medicines. New research,...
Read More